chronic hepatitis b market size, chronic hep b market, global chronic hep b market, chronic hepatitis b market share, chronic hepatitis b market growth, chronic hepatitis b market research
At what pace is the chronic hepatitis b market growing, and what is its estimated value?
The chronic hepatitis B market size has grown steadily in recent years. It will grow from $3.77 billion in 2024 to $3.94 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to advances in antiviral therapy, growing government and NGO initiatives, improved diagnostic techniques, the rising prevalence of HIV, and increasing awareness.
The chronic hepatitis B market size is expected to see steady growth in the next few years. It will grow to $4.65 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to expansion in emerging markets, growing government policies and funding, improved diagnostics and screening, rising healthcare expenditure, increasing strategic collaborations and partnerships, a growing aging population, and growing public awareness campaigns. Major trends in the forecast period include a shift towards curative therapies, expansion in emerging markets, enhanced diagnostics and screening, partnerships and collaborations, and a focus on patient-centric care.
Get Your Free Sample of The Global Chronic Hepatitis B Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17112&type=smp
What are the top drivers to the rising demand in the chronic hepatitis b market?
The high prevalence of chronic hepatitis B infection is expected to propel the growth of the chronic hepatitis B virus market going forward. Hepatitis B is a liver infection brought on by the hepatitis B virus (HBV), which is prevented through vaccination. The increase in hepatitis B infection rates is due to a combination of factors, particularly in low- and middle-income countries, due to low vaccination coverage leading to higher transmission rates as large portions of the population remain unprotected. Rising hepatitis B infection rates can increase demand for diagnostic tests and treatment options. For instance, in June 2024, according to a report published by the Centers for Disease Control and Prevention (CDC), a US-based government agency, increasing global hepatitis B vaccination coverage to 90% and treatment access to 80% could prevent 26 million new infections and 9 million deaths attributable to hepatitis B between 2022 and 2050. In 2022, there were 1.2 million new cases of hepatitis B virus (HBV) infection. Therefore, the high prevalence of hepatitis B infection will drive the chronic hepatitis B virus market.
How is the chronic hepatitis b market segmented?
The chronic hepatitis B market covered in this report is segmented –
1) By Drug Class: Antivirals, Immune Modulators
2) By Gender: Male, Female
3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers
Subsegments:
1) By Antivirals: Nucleos(T)Ide Analogs (Tenofovir, Entecavir), Interferons (Pegylated Interferon)
2) By Immune Modulators: Immune Checkpoint Inhibitors, Therapeutic Vaccines (HBV Vaccines Under Development)
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report
Who are the top competitors in the chronic hepatitis b market?
Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals
What significant trends should we anticipate in the chronic hepatitis b market over the forecast period?
Major companies operating in the chronic hepatitis B market are focusing on technological advancements such as novel antiviral therapies. Novel antiviral therapies are innovative medications targeting viral infections, especially resistant ones, by inhibiting replication and using advanced delivery systems, with ongoing clinical trials for safety and effectiveness, such as bepirovirsen for chronic hepatitis B. For instance, in February 2024, GSK plc, a UK-based multinational pharmaceutical and biotechnology company that specializes in the research, development, manufacturing, and marketing of a wide range of healthcare products, received the U.S. Food and Drug Administration (FDA) Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB). Bepirovirsen is designed to target and degrade the RNA of the hepatitis B virus (HBV), potentially allowing the immune system to regain control over the infection. The drug has demonstrated promising results in Phase IIb trials, specifically the B-Clear and B-Sure studies, where it showed efficacy in reducing hepatitis B surface antigen (HBsAg) levels and achieving sustained viral suppression.
Which regional trends are influencing the chronic hepatitis b market, and which area dominates the industry?
North America was the largest region in the chronic hepatitis B market in 2023. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Chronic Hepatitis B Market Report 2025 Offer?
The chronic hepatitis b market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Chronic hepatitis B is a long-term infection with the hepatitis B virus (HBV) lasting over six months, potentially leading to severe liver damage, liver failure, or liver cancer. It is often asymptomatic for years but can be detected through blood tests and managed with antiviral medications and regular monitoring.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17112
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
